Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for X4 Pharmaceuticals, Inc. (XFOR : NSDQ)

• Company Description    X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company's product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals Inc., formerly known as Arsanis, Inc., is based in Cambridge, United States. Number of Employees: 45

• Price / Volume Information    Yesterday's Closing Price: $4.04 Daily Weekly Monthly 20 Day Moving Average: 354,417 shares Shares Outstanding: 94.32 (millions) Market Capitalization: $381.05 (millions) Beta: 0.31 52 Week High: $4.83 52 Week Low: $1.35 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.61% -10.22% 12 Week 24.31% 14.92% Year To Date 1.00% -7.14%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 61 North Beacon Street 4th Floor - Boston,MA 02134 USA ph: 857-529-8300 fax: - ir@x4pharma.com http://www.x4pharma.com

• General Corporate Information    Officers Adam R. Craig - President and Chief Executive Officer Adam R. Craig - Executive Chairman David Kirske - Chief Financial Officer and Treasurer Michael S. Wyzga - Director Gary J. Bridger - Director Peer Information X4 Pharmaceuticals, Inc. (CORR.) X4 Pharmaceuticals, Inc. (RSPI) X4 Pharmaceuticals, Inc. (CGXP) X4 Pharmaceuticals, Inc. (BGEN) X4 Pharmaceuticals, Inc. (GTBP) X4 Pharmaceuticals, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 98420X202 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/14/26 Share - Related Items Shares Outstanding: 94.32 Most Recent Split Date: 4.00 (0.03:1) Beta: 0.31 Market Capitalization: $381.05 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.19 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.76 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.26 Price/Cash Flow: - Price / Sales: 42.27 EPS Growth vs. Year Ago Period: -500.00% vs. Previous Quarter: 27.27% Sales Growth vs. Year Ago Period: -90.60% vs. Previous Quarter: 5.45% ROE 03/31/26 - -94.90 12/31/25 - -115.27 09/30/25 - -343.67 ROA 03/31/26 - -48.09 12/31/25 - -45.97 09/30/25 - -69.77 Current Ratio 03/31/26 - 10.18 12/31/25 - 10.16 09/30/25 - 5.65 Quick Ratio 03/31/26 - 9.98 12/31/25 - 9.98 09/30/25 - 5.48 Operating Margin 03/31/26 - -1,106.30 12/31/25 - -225.55 09/30/25 - -279.86 Net Margin 03/31/26 - -1,106.30 12/31/25 - -225.55 09/30/25 - -279.86 Pre-Tax Margin 03/31/26 - -1,106.22 12/31/25 - -225.44 09/30/25 - -278.98 Book Value 03/31/26 - 1.79 12/31/25 - 2.13 09/30/25 - 2.45 Inventory Turnover 03/31/26 - 0.40 12/31/25 - 1.55 09/30/25 - 1.73 Debt-to-Equity 03/31/26 - 0.45 12/31/25 - 0.41 09/30/25 - 1.23 Debt-to-Capital 03/31/26 - 31.24 12/31/25 - 29.05 09/30/25 - 55.24

Powered by Zacks Investment Research ©